Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viatris (NASDAQ: VTRS ) issued a press release today with a slew of good news. For one thing, Viatris is acquiring two different businesses.

Viatris (VTRS) Stock Pops 17% on Acquisition News

Viatris (VTRS) delivered earnings and revenue surprises of 4.88% and 1.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q3 Earnings Beat Estimates

Oyster Point Pharma Inc

PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of TYRVAYA ® (varenicline solution) Nasal Spray and Oyster Point Pharma's pipeline.

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

Expects Biocon Biologics Transaction to Close Shortly Intends to Begin Executing on Stock Repurchase Program  Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $700-$750 Million in Cash; Expects to Close in Q1 2023 Expects Combination of Acquisitions and Share Repurchases to be Accretive to Adjusted EPS in 2023 on a Standalone Basis Anticipates Acquisitions Will Have the Potential to Add at Least $1 Billion in Net Sales and at Least $500 Million in Adjusted EBITDA by 2028 Reaffirms Total Pre-Tax Proceeds Expected from Biocon Transaction and Certain Non-Core Asset Divestitures to be up to Approximately $9 Billion  Provides Financial Targets for 2024 to 2028, Including Top-Line Total Revenues CAGR of ~3%, Adjusted EBITDA CAGR of ~4-5%, and Adjusted EPS CAGR of ~Mid-Teens Reiterates Commitment to Maintaining its Investment Grade Rating; Continues to Expect to Fully Meet Phase 1 Financial Commitments by End of 2023, Including Reducing its Gross Leverage Ratio to Approximately 3x PITTSBURGH , Nov. 7, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences and that it will provide a strategic update on its February 2022 Investor Event in a conference call and live webcast today at 8:30 a.m. ET. Under the terms of a definitive agreement, Viatris has agreed to acquire Oyster Point for $11 per share in cash upfront through a tender offer.

Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event

Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to Date Reports Total Revenues of $4.08 billion; U.S. GAAP Net Earnings of $354 million; Adjusted EBITDA of $1.50 billion; U.S. GAAP Net Cash Provided by Operating Activities of $869 million; and Free Cash Flow of $765 million Strong Year-to-Date Cash Flow; Approximately $2.81 billion of U.S. GAAP Net Cash Provided by Operating Activities and Approximately $2.56 billion in Free Cash Flow Meets Annual Target of Paying Down Approximately $2.1 billion of Debt Year to Date, One Quarter Ahead of Schedule Board of Directors Declares Quarterly Dividend of $0.12 Per Share [1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or a quantitative reconciliation of its 2022 adjusted EBITDA guidance. U.S. GAAP net cash provided by operating activities for 2022 is estimated to be between $3.1 billion and $3.3 billion.

Viatris Reports Strong Third Quarter 2022 Results

GlaxoSmithKline

The Vanguard Health Care Fund (Trades, Portfolio) disclosed in a regulatory filing that its top trades during the third quarter included the closure of its positions in Viatris Inc. ( VTRS , Financial) and Universal Health Services ( UHS , Financial), a reduction to its holding in Vertex Pharmaceuticals Inc. ( VRTX , Financial), a new holding in GSK PLC ( LSE:GSK , Financial) and a boost to its holding in DexCom ( DXCM , Financial).

Vanguard Health Care Fund Exits Viatris, Plugs Into GSK in 3rd Quarter

In the latest quarter, ignoring the quite severe effects of the dollar's appreciation, Viatris' brands performed well. But even for biosimilars, Viatris is proving portfolio value in the sale of that portfolio for a more than 10x multiple.

Viatris Asset Disposals Make The Value Case For Their Branded Portfolio

Altria

V.F.

Verizon

As you can see, I nibbled on several different positions earlier this month. Seeing some of these dividend stalwarts with yields way above their historical average was too much to ignore. Sure prices may continue to fall further but as a long time dividend investor I know that it is impossible to catch an absolute bottom.

Recent Stock Purchase October 2022

PITTSBURGH , Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J.

Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022

Company rises to the top 10% of the 800 global employers included on the list PITTSBURGH , Oct. 11, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced that it has been named to Forbes' list of World's Best Employers 2022. Viatris has received this recognition in each of its first two years since launching in 2020 as a new company.

Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row

American Airlines

Ford Motor Company

Nokia

SoFi Technologies

Telefonica SA

Bulls and bears alike have always sought out cheap stocks to buy. Most investors just can't get enough, no matter what stage we're in.

Cheap Stocks to Buy Now if You Have $100 to Spend

Viatris Inc. (NASDAQ: VTRS) shares have weakened from $10.20 to $8.42 since September 12, 2022, and the current price stands at $8.74. The U.S. stock market remains under pressure, and going forward, it will be hypersensitive to any FED comments.

Should I invest in Viatris shares after the current dip?

Pfizer

The silver lining amid the market collapse is that every new dollar put to work today in dividend stocks comes with an automatic higher yield when compared to just a few weeks ago. First up, I'm thinking about adding to recent spin-off Viatris Inc.

October 2022 Stock Considerations

Kraft Heinz

These stocks are distributing dividends yielding more than 4%.

2 Dirt-Cheap Dividend Stocks Trading Below Their Book Values

We were cautious on Viatris as we felt the three headwinds we anticipated would lead to a guidance cut. We were partially correct on that outcome, but the stock still went lower despite holding the free cash flow outlook.

Take These Broken Wings And Learn To Fly Again Viatris

Viatris Inc. (NASDAQ:VTRS ) BofA Global Research Global Healthcare Conference September 15, 2022 11:45 AM ET Company Participants Michael Goettler – Chief Executive Officer Rajiv Malik – President Sanjeev Narula – Chief Financial Officer Conference Call Participants Jason Gerberry – BofA Securities Jason Gerberry Well, good day, everybody. Thanks for joining us at the BofA London Healthcare Conference.

Viatris Inc.'s (VTRS) BofA Global Research Global Healthcare Conference Transcript

Apple

Bristol-Myers

FedEx

Intel

Mastercard

Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer.

7 Screaming Buy Stock Picks to Beat the September Market Slump

Its top-line troubles could be transient, but there's a risk they won't be.

Is Viatris Stock a Buy Now?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

Why Is Viatris (VTRS) Down 10% Since Last Earnings Report?

With all the recent market volatility, there is no shortage of stocks that are looking seemingly cheaper when compared to the closing months of 2021. First up, I'm thinking about adding to the recent spin-off Viatris Inc.

September 2022 Stock Considerations

PITTSBURGH , Sept. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022.

Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference

Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020.

Viatris: 5% Dividend Yield Is A Threat For Investors

Diageo

Paramount Global

Scotts Miracle-Gro

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

The stock market took a nose dive on August 26th, shedding over 3% in some instances on the overall valuation of the stock market. Diageo yields well above the S&P 500 and is a better yield on average than the majority of high quality stocks.

Dividend Stock Watch List: Lanny's September 2022 Edition

Chevron

AT&T

From healthcare to oil and gas to telecom, these stocks can also help diversify your portfolio.

3 of the Best Dividend Stocks to Buy in September

Viatris reported encouraging earnings numbers earlier this month.

News for Viatris Stock (VTRS)